{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:11:12Z","timestamp":1756635072342},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T00:00:00Z","timestamp":1336694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11906-012-0268-5","type":"journal-article","created":{"date-parts":[[2012,5,10]],"date-time":"2012-05-10T16:34:18Z","timestamp":1336667658000},"page":"350-359","source":"Crossref","is-referenced-by-count":11,"title":["Recent Clinical Trials in Atrial Fibrillation in Hypertensive Patients"],"prefix":"10.1007","volume":"14","author":[{"given":"Athanasios J.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolis S.","family":"Kallistratos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonidas E.","family":"Poulimenos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,11]]},"reference":[{"key":"268_CR1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285:2370\u20135.","journal-title":"JAMA"},{"key":"268_CR2","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1161\/01.CIR.0000083722.42033.0A","volume":"108","author":"WA Wattigney","year":"2003","unstructured":"Wattigney WA, Mensah GA, Croft JB, et al. Increasing trends in hospitalization for atrial fibrillation in the USA, 1985 through 1999; implications for primary prevention. Circulation. 2003;108:711\u20136.","journal-title":"Circulation"},{"key":"268_CR3","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","volume":"271","author":"EJ Benjamin","year":"1994","unstructured":"Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840\u20134.","journal-title":"JAMA"},{"key":"268_CR4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"\u2022\u2022 Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. Major II inhibitor Dabigatran publication presenting the results of the RELY trial.","journal-title":"N Engl J Med"},{"key":"268_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"\u2022\u2022 Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391. Major Xa inhibitor rivaroxaban publication presenting the results of the ROCKET AF trial.","journal-title":"N Engl J Med"},{"key":"268_CR6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med"},{"key":"268_CR7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"\u2022\u2022 Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. Major Xa inhibitor apixaban publication presenting the results of the ARISTOTLE trial.","journal-title":"N Engl J Med"},{"key":"268_CR8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946\u201352.","journal-title":"Circulation"},{"key":"268_CR9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","volume":"22","author":"PA Wolf","year":"1991","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983\u20138.","journal-title":"Stroke"},{"key":"268_CR10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1076-7460.2005.02278.x","volume":"14","author":"AS Go","year":"2005","unstructured":"Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005;14:56\u201361.","journal-title":"Am J Geriatr Cardiol"},{"key":"268_CR11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0002-9343(02)01479-1","volume":"114","author":"S Penado","year":"2003","unstructured":"Penado S, Cano M, Acha O, et al. Atrial fibrillation as a risk factor for stroke recurrence. Am J Med. 2003;114:206\u201310.","journal-title":"Am J Med"},{"key":"268_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.hrthm.2009.12.004","volume":"7","author":"TJ Bunch","year":"2010","unstructured":"Bunch TJ, Weiss JP, Crandall BG, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer\u2019s dementia. Hear Rhythm. 2010;7:433\u20137.","journal-title":"Hear Rhythm"},{"key":"268_CR13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1540-8159.2000.tb00794.x","volume":"23","author":"I Savelieva","year":"2000","unstructured":"Savelieva I, Camm AJ. Silent atrial fibrillation\u2013another Pandora\u2019s box. Pacing Clin Electrophysiol. 2000;23:145\u20138.","journal-title":"Pacing Clin Electrophysiol"},{"key":"268_CR14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1161\/01.CIR.0000051455.44919.73","volume":"107","author":"RL Page","year":"2003","unstructured":"Page RL, Tilsch TW, et al. Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators. Asymptomatic or \u2018silent\u2019 atrial fibrillation: frequency in untreated patients and patients receiving azimilide. Circulation. 2003;107:1141\u20135.","journal-title":"Circulation"},{"key":"268_CR15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1105575","volume":"366","author":"JS Healey","year":"2012","unstructured":"\u2022\u2022 Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke N. Engl J Med. 2012;366:120\u20139. Results of the ASSERT study highlighting the significance of silent or subclinical AF revealed in patients with pacemakers.","journal-title":"Engl J Med"},{"key":"268_CR16","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/archinternmed.2010.434","volume":"170","author":"RB Schnabel","year":"2010","unstructured":"Schnabel RB, Aspelund T, Li G, et al. Validation of an atrial fibrillation risk algorithm in whites and African Americans. Arch Intern Med. 2010;170:1909\u201317.","journal-title":"Arch Intern Med"},{"key":"268_CR17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/bmj.39227.551713.AE","volume":"335","author":"J Mant","year":"2007","unstructured":"Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. BMJ. 2007;335:380.","journal-title":"BMJ"},{"key":"268_CR18","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.jacc.2004.11.070","volume":"45","author":"JS Healey","year":"2005","unstructured":"Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J Am Coll Cardiol. 2005;45:1832\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0091270005283284","volume":"46","author":"JS Kalus","year":"2006","unstructured":"Kalus JS, Coleman CI, White CM. The impact of suppressing the renin angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46:21\u20138.","journal-title":"J Clin Pharmacol"},{"key":"268_CR20","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jacc.2010.01.043","volume":"55","author":"MP Schneider","year":"2010","unstructured":"\u2022 Schneider MP, Hua TA, Bohm M, et al. Prevention of atrial fibrillation by renin-angiotensin system-inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299\u2013307. RAS system inhibition efficacy in AF prevention.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR21","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","volume":"26","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Kjeldsen SE, Julius S, et al. VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26:403\u201311.","journal-title":"J Hypertens"},{"key":"268_CR22","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","volume":"45","author":"K Wachtell","year":"2005","unstructured":"Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR23","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"S Yusuf","year":"2008","unstructured":"ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547\u201359.","journal-title":"N Engl J Med"},{"key":"268_CR24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","author":"S Yusuf","year":"2008","unstructured":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174\u201383.","journal-title":"Lancet"},{"key":"268_CR25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","volume":"359","author":"S Yusuf","year":"2008","unstructured":"Yusuf S, Diener HC, Sacco RL, PRoFESS Study Group, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:1225\u201337.","journal-title":"N Engl J Med"},{"key":"268_CR26","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.amjcard.2007.01.030","volume":"99","author":"A Tveit","year":"2007","unstructured":"Tveit A, Seljeflot I, Grundvold I, et al. Effect of candesartan and various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation. Am J Cardiol. 2007;99:1544\u20138.","journal-title":"Am J Cardiol"},{"key":"268_CR27","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","volume":"360","author":"M Disertori","year":"2009","unstructured":"GISSI-AF Investigators, Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606\u201317.","journal-title":"N Engl J Med"},{"key":"268_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","volume":"5","author":"A Goette","year":"2012","unstructured":"Goette A, Sch\u00f6n N, Kirchhof P, et al. Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF)-Trial. Circ Arrhythm Electrophysiol. 2012;5:43\u201351.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"268_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/eurheartj\/ehl484","volume":"28","author":"IA Nasr","year":"2007","unstructured":"Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007;28:457\u201362.","journal-title":"Eur Heart J"},{"key":"268_CR30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-152-2-201001190-00005","volume":"152","author":"BA Schaer","year":"2010","unstructured":"Schaer BA, Schneider C, Jick SS, Conen D, Osswald S, Meier CR. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med. 2010;152:78\u201384.","journal-title":"Ann Intern Med"},{"key":"268_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jacc.2004.03.056","volume":"44","author":"PL L'Allier","year":"2004","unstructured":"L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004;44:159\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"268_CR33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/CIRCEP.109.870204","volume":"2","author":"PR Kowey","year":"2009","unstructured":"Kowey PR, Dorian P, Mitchell LB, for the Atrial Arrhythmia Conversion Trial Investigators, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"268_CR34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","volume":"57","author":"AJ Camm","year":"2011","unstructured":"\u2022 Camm AJ, Capucci A, Hohnloser SH, on behalf of the AVRO Investigators, et al. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313\u201321. Study of Vernakalant vs Amiodarone showing enhanced efficacy of the new drug versus the current standard of care.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR35","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"\u2022\u2022 EHRA,EACTS, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u2013429. Current ESC AF guidelines.","journal-title":"Eur Heart J"},{"key":"268_CR36","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1056\/NEJMoa1109867","volume":"365","author":"SJ Connolly","year":"2011","unstructured":"\u2022 Connolly SJ, Camm AJ, Halperin JL, PALLAS Investigators, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268\u201376. The PALLAS study that raised serious points concerning the safety of Dronedarone and was prematurely terminated for these reasons.","journal-title":"N Engl J Med"},{"key":"268_CR37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa1001337","volume":"362","author":"IC Gelder Van","year":"2010","unstructured":"\u2022\u2022 Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363\u201373. A very important study highlighting the value of less strict rate control in AF.","journal-title":"N Engl J Med"},{"key":"268_CR38","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa021328","volume":"347","author":"The AFFIRM Investigators","year":"2002","unstructured":"The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825\u201333.","journal-title":"N Engl J Med"},{"key":"268_CR39","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/j.jacc.2011.07.036","volume":"58","author":"S Saksena","year":"2011","unstructured":"Saksena S, Slee A, Waldo AL, et al. Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol. 2011;58:1975\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"268_CR40","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/j.1540-8167.2011.02035.x","volume":"22","author":"TJ Bunch","year":"2011","unstructured":"Bunch TJ, Crandall BG, Weiss JP, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22:839\u201345.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"268_CR41","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","volume":"41","author":"GY Lip","year":"2010","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731\u20138.","journal-title":"Stroke"},{"key":"268_CR42","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"\u2022\u2022 Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100. The first publication of the HAS BLED score which since has become the standard of care for AF patients and a guideline \u2013 endorsed practice.","journal-title":"Chest"},{"issue":"12","key":"268_CR43","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjmed.2011.06.009","volume":"124","author":"G Piazza","year":"2011","unstructured":"Piazza G, Nguyen TN, Cios D, et al. Anticoagulation-associated adverse drug events. Am J Med. 2011;124(12):1136\u201342.","journal-title":"Am J Med"},{"key":"268_CR44","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","volume":"123","author":"IM Ogilvie","year":"2010","unstructured":"Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638\u201345.","journal-title":"Am J Med"},{"key":"268_CR45","doi-asserted-by":"crossref","first-page":"e000269","DOI":"10.1136\/bmjopen-2011-000269","volume":"1","author":"S Lee","year":"2011","unstructured":"Lee S, Shafe ACE, Cowie MR. UK stroke incidence, mortality and cardiovascular risk management 1999-2008: time-trend analysis from the General Practice Research Database. BMJ Open. 2011;1:e000269. doi: 10.1136\/bmjopen-2011-000269 .","journal-title":"BMJ Open"},{"key":"268_CR46","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIR.0b013e31820f14c0","volume":"123","author":"LS Wann","year":"2011","unstructured":"\u2022\u2022 Wann LS, Curtis AB, Ellenbogen KA, et al. ACCF\/AHA\/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2011;123:1144\u201350. The first recommendation on the use of non VKA anticoagulants for AF.","journal-title":"Circulation"},{"key":"268_CR47","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1161\/CIRCULATIONAHA.110.985655","volume":"123","author":"SV Shah","year":"2011","unstructured":"Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011;123:2562\u201370.","journal-title":"Circulation"},{"key":"268_CR48","doi-asserted-by":"crossref","unstructured":"\u2022 Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172:397\u2013402. Is there an increased risk of acute coronary events by the use of Dabigatran?","DOI":"10.1001\/archinternmed.2011.1666"},{"key":"268_CR49","doi-asserted-by":"crossref","unstructured":"\u2022 Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012;125:669\u201376. Is there an increased risk of acute coronary events by the use of Dabigatran?","DOI":"10.1161\/CIRCULATIONAHA.111.055970"},{"key":"268_CR50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"\u2022 Mega JL, Braunwald E, Wiviott SD, ATLAS ACS 2\u2013TIMI 51 Investigators, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9\u201319. A positive result study on the efficacy of rivaroxaban in Acute Coronary Syndromes.","journal-title":"N Engl J Med"},{"issue":"8","key":"268_CR51","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, APPRAISE-2 Investigators, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699\u2013708.","journal-title":"N Engl J Med"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-012-0268-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-012-0268-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:14:29Z","timestamp":1559434469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-012-0268-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,11]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1007\/s11906-012-0268-5","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,11]]}}}